Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Hyundai Motor Union Launches First Full Strike in Decade Over Wages, AI Job Risks 
Alibaba Shares Fall as AI Spending Hits Profit 
Samsung Shares Rise on $72 Billion Shareholder Return Plan 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
Add as a preferred source on Google
LONDON, May 04, 2018 -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Piers Morgan, Chief Financial Officer of Verona Pharma, will present at Bio€quity Europe 2018 to be held May 14-16, 2018 in Ghent, Belgium.
Piers Morgan, Chief Financial Officer is scheduled to present Tuesday, May 15th at 5:20 PM CEST. For more information please visit www.veronapharma.com
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has shown clinically meaningful and statistically significant improvements in lung function and clinical symptoms as compared to placebo, and has shown statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators as compared to such bronchodilators administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma.
| For further information, please contact: | |
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
| Jan-Anders Karlsson, Chief Executive Officer | [email protected] |
| Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) | Tel: +44 (0) 20 7710 7600 |
| Stewart Wallace / Jonathan Senior / Ben Maddison | [email protected] |
| FTI Consulting (UK Media and Investor enquiries) | Tel: +44 (0)20 3727 1000 |
| Simon Conway / Natalie Garland-Collins | [email protected] |
| ICR, Inc. (US Media and Investor enquiries) | |
| James Heins | Tel: +1 203-682-8251 [email protected] |
| Stephanie Carrington | Tel. +1 646-277-1282 [email protected] |
